From: Arginase 1 Deficiency: using genetic databases as a tool to establish global prevalence
Country | ARG1 carrier frequency | ARG1-D baseline birth prevalence (births/million) | ARG1-D adjusted birth prevalencea (95% CI) |
---|---|---|---|
Argentina | 0.0017 | 2.85 | 3.06 (2.11–4.56) |
Australia | 0.0010 | 0.99 | 1.11 (0.87–1.55) |
Austria | 0.0009 | 0.90 | 1.19 (0.98–1.53) |
Bahrain | 0.0011 | 1.27 | 6.05 (4.78–8.23) |
Belgium | 0.0009 | 0.87 | 1.46 (1.23–1.84) |
Brazil | 0.0013 | 1.81 | 2.90 (2.19–4.02) |
Canada | 0.0010 | 1.00 | 1.94 (1.55–2.62) |
Chile | 0.0016 | 2.62 | 3.33 (2.37–4.82) |
Colombia | 0.0016 | 2.64 | 3.76 (2.70–5.41) |
Croatia | 0.0009 | 0.88 | 0.94 (0.76–1.23) |
Czech Republic | 0.0009 | 0.82 | 0.93 (0.76–1.25) |
Denmark | 0.0009 | 0.89 | 1.59 (1.35–1.97) |
Finland | 0.0009 | 0.90 | 0.96 (0.77–1.27) |
France | 0.0010 | 1.03 | 1.54 (1.24–2.04) |
Germany | 0.0009 | 0.86 | 1.27 (1.06–1.62) |
Ireland | 0.0009 | 0.89 | 1.19 (0.97–1.55) |
Israel | 0.0010 | 0.92 | 7.79 (6.80–9.36) |
Italy | 0.0010 | 0.91 | 1.21 (0.99–1.56) |
Japan | 0.0013 | 1.69 | 4.86 (3.46–7.43) |
South Korea | 0.0013 | 1.70 | 1.70 (1.02–3.15) |
Kuwait | 0.0011 | 1.21 | 12.97 (10.58–16.92) |
Mexico | 0.0016 | 2.55 | 2.85 (1.99–4.20) |
Netherlands | 0.0010 | 0.91 | 1.03 (0.82–1.38) |
New Zealand | 0.0010 | 0.93 | 1.05 (0.82–1.49) |
Norway | 0.0009 | 0.87 | 0.92 (0.75–1.22) |
Poland | 0.0009 | 0.88 | 1.17 (0.97–1.50) |
Portugal | 0.0010 | 0.91 | 1.81 (1.53–2.24) |
Qatar | 0.0012 | 1.35 | 17.48 (13.95–23.28) |
Russian Federation | 0.0009 | 0.88 | 1.29 (1.08–1.63) |
Saudi Arabia | 0.0010 | 0.95 | 14.63 (12.79–17.48) |
Spain | 0.0010 | 0.96 | 3.47 (2.98–4.22) |
Sweden | 0.0009 | 0.85 | 1.20 (1.00–1.54) |
Switzerland | 0.0009 | 0.86 | 1.21 (1.01–1.56) |
Taiwan | 0.0013 | 1.70 | 3.17 (2.15–5.14) |
Turkey | 0.0009 | 0.89 | 6.32 (5.59–7.39) |
United Arab Emirates | 0.0012 | 1.33 | 12.81 (10.09–17.44) |
United Kingdom | 0.0010 | 0.91 | 1.15 (0.92–1.55) |
United States | 0.0012 | 1.35 | 1.50 (1.09–2.20) |